Biologics CDMO Market, By Biologics Type (Cell and Gene Therapies, Monoclonal Antibodies, Recombinant Proteins, and Vaccines), By Production Technology, By Service Type, By Scale of Operation, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4890
|
Published Date
March 2026
|
Pages
347
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Biologics CDMO Market size was valued at US$21,975.98 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.
The Biologics CDMO (Contract Development and Manufacturing Organization) market consists of specialized service providers that support biopharmaceutical companies in the development, production, and commercialization of biologic drugs. These organizations deliver comprehensive services such as cell line development, process optimization, analytical testing, and large-scale manufacturing.
Biologics CDMOs utilize advanced bioprocessing technologies, automation, and robust quality management systems to maintain regulatory compliance, ensure consistent product quality, and improve operational efficiency. By outsourcing these complex processes to CDMOs, pharmaceutical companies can accelerate time-to-market, reduce operational challenges, and lower production costs. Through scalable and flexible manufacturing capabilities, biologics CDMOs play a vital role in supporting the development of innovative therapies and expanding patient access to safe and effective biologic treatments. For instance, agencies such as the U.S. Food and Drug Administration, European Medicines Agency, and the World Health Organization continue to promote the development and approval of biologics and biosimilars to improve treatment accessibility.
Biologics CDMO Market- Market Dynamics
Growing Demand for Biologic Therapies
The rising demand for biologic therapies is a major factor driving growth in the biologics CDMO market. Biologics—such as monoclonal antibodies, vaccines, recombinant proteins, and cell- and gene-based therapies—are increasingly used to treat complex diseases including cancer, autoimmune disorders, and rare genetic conditions. As the pipeline of biologic drugs continues to expand, biopharmaceutical companies are increasingly outsourcing development and manufacturing activities to Contract Development and Manufacturing Organizations (CDMOs) to access specialized expertise, advanced technologies, and scalable production infrastructure. This outsourcing trend enables CDMOs to enhance production capacity, streamline operational processes, and provide integrated end-to-end services ranging from early-stage development to commercial manufacturing. In the biologics CDMO ecosystem, this demand supports faster process development, flexible manufacturing capabilities, and high-quality production that meets strict global regulatory standards. As a result, CDMOs help biopharmaceutical companies accelerate time-to-market, maintain product consistency, and optimize operational resources.
Growing demand is also encouraging investments in advanced bioprocessing technologies, automation systems, and sophisticated analytical platforms, enabling CDMOs to efficiently manage larger production volumes and increasingly complex biologic molecules. For example, the biotechnology sector in India has experienced significant expansion over the past decade. The industry grew from approximately US$10 billion in 2015 to over US$100 billion by 2024, driven by increasing exports, supportive government initiatives, and a strong pool of skilled professionals. In addition, the broader pharmaceutical and biotechnology sector in India was valued at around US$55 billion in FY25 and is projected to reach nearly US$130 billion by 2030. These developments highlight the country’s strengthening position in the global biologics and biosimilars landscape, supported by favorable policies and expanding manufacturing capabilities.
Biologics CDMO Market- Segmentation Analysis:
The Global Biologics CDMO Market is segmented on the basis of Biologics Type, Production Technology, Service Type, Scale of Operation, End User, and Region.
The biologics CDMO market can be segmented by biologic type into monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. Among these, the monoclonal antibodies segment represents a substantial share of the market due to its extensive therapeutic applications and strong demand across areas such as oncology, autoimmune disorders, and infectious diseases. The growing demand for monoclonal antibodies reflects the increasing need for targeted and highly effective biologic treatments capable of addressing complex and chronic conditions. To meet this demand, biologics CDMOs focus on optimized process development, large-scale production capabilities, and strict quality control measures. These capabilities enable efficient manufacturing and ensure the timely availability of monoclonal antibody therapies, supporting broader patient access to critical biologic treatments. For example, in 2024, reports associated with the U.S. Government indicated that monoclonal antibodies have become one of the fastest-growing classes of therapeutic agents worldwide. The global monoclonal antibody market was valued at approximately USD 205 billion in 2023 and is projected to exceed USD 300 billion by 2030. By 2023, more than 120 monoclonal antibody therapies had been approved globally, with expanding distribution in low- and middle-income countries improving access to these advanced treatments. This trend demonstrates how rising demand for targeted biologic therapies is encouraging greater investment in manufacturing capacity, regulatory support, and international collaboration.
The biologics CDMO market can also be categorized by production technology, including mammalian cell culture, microbial fermentation, and plant-based expression systems. Among these technologies, mammalian cell culture holds a prominent market share due to its ability to produce complex biologics with accurate post-translational modifications and high structural fidelity. High efficiency and versatility in production refer to the capability of a manufacturing platform to consistently generate large quantities of biologics while maintaining product quality and biological functionality. Mammalian cell culture systems provide biologics CDMOs with the flexibility required to manufacture complex molecules such as monoclonal antibodies and recombinant proteins with high precision and reproducibility. This technology supports scalable production, improved yields, and reliable product quality, enabling CDMOs to meet increasing global demand for biologic therapies. Growing technological innovation and continued investment in advanced bioprocessing platforms further strengthen the ability of biologics CDMOs to support the expanding pipeline of complex biologic medicines worldwide.
Biologics CDMO Market- Geographical Insights
The Biologics CDMO market demonstrates notable regional differences, influenced by variations in biopharmaceutical manufacturing capabilities, regulatory environments, research investment, and technological adoption. North America maintains a strong position in the market, supported by advanced biologics manufacturing infrastructure, significant research and development investments, and a high level of outsourcing by biopharmaceutical companies. Countries such as the United States and Canada benefit from established biotechnology ecosystems, strong regulatory oversight, and continuous innovation in biologic drug development. Government regulatory data highlights the growing importance of biologics; for example, the U.S. Food and Drug Administration approved 50 new drugs in 2024, of which 16 were biologics, representing about 32% of total approvals, demonstrating the expanding role of biologic therapies in modern medicine.
Europe also represents an important market, characterized by increasing investment in biologics manufacturing, favorable regulatory frameworks, and the growing adoption of advanced bioprocessing technologies. Countries including Germany, France, and the United Kingdom contribute significantly to regional growth through expanding research activities and strong pharmaceutical industries. The Asia-Pacific region is experiencing rapid expansion due to increasing biopharmaceutical production, rising healthcare expenditures, and supportive government initiatives aimed at strengthening biologics development. Countries such as China, India, Japan, and South Korea are emerging as important hubs for biologics manufacturing and outsourcing services, supported by growing technical expertise and expanding manufacturing infrastructure. Meanwhile, regions including Latin America, the Middle East, and Africa are gradually increasing their participation in the biologics CDMO market. Improvements in regulatory frameworks, expanding healthcare systems, and the development of local biomanufacturing capabilities are encouraging greater outsourcing of biologics development and production activities in these regions.
United States Biologics CDMO Market – Country Insights
The United States Biologics CDMO market is witnessing steady growth, supported by a well-established biopharmaceutical ecosystem and the increasing trend of outsourcing biologics development and manufacturing activities. Pharmaceutical and biotechnology companies are increasingly collaborating with Contract Development and Manufacturing Organizations (CDMOs) to accelerate drug development timelines, expand production capacity, and maintain compliance with strict regulatory standards. The presence of several leading CDMO providers, along with policies that support biotechnology innovation and advanced drug manufacturing, continues to drive market expansion in the country. In addition, the growing focus on scalable, cost-efficient, and high-quality biologics production is encouraging wider adoption of CDMO services across both clinical and commercial development stages. Outsourcing allows companies to leverage specialized expertise, advanced bioprocessing technologies, and established manufacturing infrastructure without making large capital investments.
For example, in January 2024, data published by the Drug, Chemical & Associated Technologies Association (DCAT) indicated that the global CDMO market is projected to grow at an annualized rate of approximately 7.29% through 2028. Within this broader market, the biologics CDMO segment is expected to expand from about US$15.1 billion in 2023 to nearly US$27.0 billion by 2028, representing a compound annual growth rate (CAGR) of around 12.3%. This growth is largely driven by expanding biotechnology pipelines and increasing demand for complex biologics as well as cell- and gene-therapy manufacturing services, highlighting how continued investment and outsourcing trends are shaping the bio/pharmaceutical manufacturing landscape.
Biologics CDMO Market- Competitive Landscape:
The Biologics CDMO market is moderately concentrated, with several global contract development and manufacturing organizations competing to provide specialized biologics development and production services. Major industry participants include 3P Biopharmaceuticals, AGC Biologics, Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd., Evonik Industries AG, Rentschler Biopharma SE, Lonza Group, Samsung Biologics, WuXi AppTec, Catalent, Fujifilm Diosynth Biotechnologies, Recipharm, KBI Biopharma, Avid Bioservices, AbbVie Inc., BioReliance, Thermo Fisher Scientific, and Eurofins Scientific.
These companies compete by offering integrated biologics development and manufacturing services, including cell line development, process optimization, clinical and commercial manufacturing, analytical testing, and quality assurance. The growing complexity of biologic drugs is encouraging CDMOs to invest in advanced bioprocessing technologies, automation, and high-capacity manufacturing facilities to support the evolving needs of biopharmaceutical companies. For example, in 2024, Lonza Group expanded its biologics manufacturing capabilities by integrating continuous bioprocessing technologies, enabling higher production efficiency and reducing development timelines for complex biologic therapies. Increasing demand for innovative biologics—such as monoclonal antibodies, recombinant proteins, and cell- and gene-based therapies—continues to drive competition and innovation within the CDMO sector. To remain competitive, many providers are also expanding their service portfolios to include advanced analytical testing, regulatory support, and scalable manufacturing solutions that help accelerate global access to high-quality biologic treatments.
Recent Developments
- July 2024: Bora Pharmaceuticals Co. Ltd. announced a strategic collaboration with a leading biopharmaceutical innovator to strengthen its biologics CDMO capabilities and accelerate process development for complex biologic therapies. The partnership focuses on leveraging advanced bioprocessing platforms and integrated analytics to enhance manufacturing efficiency and shorten drug development timelines, reinforcing the company’s position in high-performance biologics manufacturing.
- January 2025: Evonik Industries AG introduced a significant expansion of its biologics CDMO services through collaborations with global biopharmaceutical partners. The initiative involves the implementation of next-generation cell culture and purification technologies aimed at improving product quality, reducing production timelines, and meeting the growing global demand for complex biologic therapies. This development further strengthens Evonik’s role as a key provider of advanced biologics manufacturing solutions in the evolving CDMO landscape.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOLOGICS CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- AGC Biologics
- Avid Bioservices
- Binex Co. Ltd.
- Bioreliance
- Bora Pharmaceuticals Co. Ltd.
- Catalent
- Eurofins Scientific
- Evonik Industries AG
- Fujifilm Diosynth Biotechnologies
- KBI Biopharma
- Lonza
- Recipharm
- Rentschler Biopharma SE
- Samsung Biologics
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- 3P Biopharmaceuticals S.L.U.
- Others
GLOBALBIOLOGICS CDMO MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032
- Cell and Gene Therapies
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
GLOBAL BIOLOGICS CDMO MARKET, BY PRODUCTION TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- Plant-based Expression Systems
- Mammalian Cell Culture
- Microbial Fermentation
GLOBAL BIOLOGICS CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032
- Analytical Development
- Clinical Manufacturing
- Commercial Manufacturing
- Process Development
- Quality Control Testing
GLOBAL BIOLOGICS CDMO MARKET, BY SCALE OF OPERATION- MARKET ANALYSIS, 2019 - 2032
- Large Scale
- Medium Scale
- Small Scale
GLOBAL BIOLOGICS CDMO MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Academic Institutions
- Pharmaceutical Companies
- Biotechnology Companies
GLOBAL BIOLOGICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Biologics CDMO Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Biologics CDMO Market Snippet by Biologics Type
2.1.2. Biologics CDMO Market Snippet by Production Technology
2.1.3. Biologics CDMO Market Snippet by Service Type
2.1.4. Biologics CDMO Market Snippet by Scale of Operation
2.1.5. Biologics CDMO Market Snippet by End User
2.1.6. Biologics CDMO Market Snippet by Country
2.1.7. Biologics CDMO Market Snippet by Region
2.2. Competitive Insights
3. Biologics CDMO Key Market Trends
3.1. Biologics CDMO Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Biologics CDMO Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Biologics CDMO Market Opportunities
3.4. Biologics CDMO Market Future Trends
4. Biologics CDMO Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Biologics CDMO Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Biologics CDMO Market Landscape
6.1. Biologics CDMO Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Biologics CDMO Market – By Biologics Type
7.1. Overview
7.1.1. Segment Share Analysis, By Biologics Type, 2024&2032 (%)
7.1.2. Cell and Gene Therapies
7.1.3. Monoclonal Antibodies
7.1.4. Recombinant Proteins
7.1.5. Vaccines
8. Biologics CDMO Market – By Production Technology
8.1. Overview
8.1.1. Segment Share Analysis, By Production Technology, 2024&2032 (%)
8.1.2. Plant-based Expression Systems
8.1.3. Mammalian Cell Culture
8.1.4. Microbial Fermentation
9. Biologics CDMO Market – By Service Type
9.1. Overview
9.1.1. Segment Share Analysis, By Service Type, 2024&2032 (%)
9.1.2. Analytical Development
9.1.3. Clinical Manufacturing
9.1.4. Commercial Manufacturing
9.1.5. Process Development
9.1.6. Quality Control Testing
10. Biologics CDMO Market – By Scale of Operation
10.1. Overview
10.1.1. Segment Share Analysis, By Scale of Operation, 2024&2032 (%)
10.1.2. Large Scale
10.1.3. Medium Scale
10.1.4. Small Scale
11. Biologics CDMO Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
11.1.2. Academic Institutions
11.1.3. Pharmaceutical Companies
11.1.4. Biotechnology Companies
12. Biologics CDMO Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Biologics CDMO Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Biologics CDMO Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Biologics CDMO Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. PhilippinesMarket Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Biologics CDMO Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Biologics CDMO Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Biologics CDMO Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. AbbVie Inc.
13.2.2. AGC Biologics
13.2.3. Avid Bioservices
13.2.4. Binex Co. Ltd.
13.2.5. Bioreliance
13.2.6. Bora Pharmaceuticals Co. Ltd.
13.2.7. Catalent
13.2.8. Eurofins Scientific
13.2.9. Evonik Industries AG
13.2.10. Fujifilm Diosynth Biotechnologies
13.2.11. KBI Biopharma
13.2.12. Lonza
13.2.13. Recipharm
13.2.14. Rentschler Biopharma SE
13.2.15. Samsung Biologics
13.2.16. Thermo Fisher Scientific Inc.
13.2.17. WuXi AppTec
13.2.18. 3P Biopharmaceuticals S.L.U.
13.2.19. Others
14. 360 Degree AnalystView
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOLOGICS CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- AGC Biologics
- Avid Bioservices
- Binex Co. Ltd.
- Bioreliance
- Bora Pharmaceuticals Co. Ltd.
- Catalent
- Eurofins Scientific
- Evonik Industries AG
- Fujifilm Diosynth Biotechnologies
- KBI Biopharma
- Lonza
- Recipharm
- Rentschler Biopharma SE
- Samsung Biologics
- Thermo Fisher Scientific Inc.
- WuXi AppTec
- 3P Biopharmaceuticals S.L.U.
- Others
GLOBALBIOLOGICS CDMO MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032
- Cell and Gene Therapies
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
GLOBAL BIOLOGICS CDMO MARKET, BY PRODUCTION TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- Plant-based Expression Systems
- Mammalian Cell Culture
- Microbial Fermentation
GLOBAL BIOLOGICS CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032
- Analytical Development
- Clinical Manufacturing
- Commercial Manufacturing
- Process Development
- Quality Control Testing
GLOBAL BIOLOGICS CDMO MARKET, BY SCALE OF OPERATION- MARKET ANALYSIS, 2019 - 2032
- Large Scale
- Medium Scale
- Small Scale
GLOBAL BIOLOGICS CDMO MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Academic Institutions
- Pharmaceutical Companies
- Biotechnology Companies
GLOBAL BIOLOGICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
